Cordlife
Cordlife Group Limited operates Asia's largest network of private cord-blood and cord lining stem cell banks across 10 markets, serving over 600,000 families with cryogenic storage, diagnostic services, and the Cordlife Care 360° protection package.
- Company typePublic
- Founded2001
- HeadquartersSingapore, Singapore
- Headcount51–100
- GTM typeB2C
- OfferingServices
What Cordlife does
Cordlife Group Limited is a Singapore-headquartered, Mainboard-listed (SGX, since 2012) consumer healthcare company founded in May 2001 that pioneered private cord-blood banking in Asia. Its core offering is the collection, processing, and long-term cryogenic storage of umbilical cord blood and cord lining stem cells — a one-time, biological-insurance product collected at birth and held under multi-decade storage contracts. The company operates what it describes as Asia's largest network of cord blood banks, with six full stem cell banking facilities across Singapore, Hong Kong, India, Malaysia, Indonesia, and the Philippines, plus market presence in Vietnam and Myanmar and an indirect Thai stake via subsidiary Stemlife Berhad. Over 600,000 parents in Asia have entrusted Cordlife with samples, and 85+ cord-blood units have been released to 25 healthcare institutions in 10 countries for transplant or cellular therapy.
Beyond stem-cell banking, Cordlife provides a suite of diagnostics services aimed at expectant mothers and newborns: non-invasive prenatal testing (NIPT), paediatric vision screening, and newborn metabolic screening. The Cordlife Care 360° add-on package layers financial-assurance and insurance coverage (transplant cost coverage up to S$50,000, worldwide delivery, parental death/disability support, viable match guarantees, pre-transplant testing, professional indemnity, and pregnancy complication coverage) on top of core storage. The technology backbone centres on proprietary cryopreservation and Cordlife's CellOptima cord lining platform, supported by an Enhanced Lab Monitoring System with 24/7 real-time on-site and remote surveillance.
The go-to-market is a direct-to-consumer, sales-led model. Expectant parents enroll via a customer hotline, online enquiry, or physical/virtual consultation; the company then operates hospital collection partnerships across major Singapore providers (KKH, SGH, NUH, Mount Elizabeth, Gleneagles, Raffles, Thomson Medical, Mount Alvernia, Parkway East) and drives top-of-funnel awareness through education-led content, social media, baby fairs, and antenatal talks. Revenue is generated via one-time collection and processing fees plus recurring annual storage fees, with Child Development Account (CDA) payment accepted in Singapore. As of October 2025 Singapore's Ministry of Health imposed a potential one-year suspension following compliance failures, and on 14 January 2026 Cordlife received a restricted one-year licence renewal that prohibits new collection, testing, or storage of cord-blood units in Singapore — limiting operations to storage, transfer, and retrieval of existing units; the group is also facing civil claims of at least S$5.45 million for 109 allegedly damaged units and an FY2025 disclaimer of audit opinion from PKF-CAP.
Cordlife firmographics
Firmographics- Name
- Cordlife
- Legal name
- Cordlife Group Limited
- Website
- https://cordlife.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cordlife Group Limited operates Asia's largest network of private cord-blood and cord lining stem cell banks across 10 markets, serving over 600,000 families with cryogenic storage, diagnostic services, and the Cordlife Care 360° protection package.
- Ownership category
- akta.pro rank
Cordlife industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
Keywords
Where Cordlife is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices8 records
Markets served
Cordlife business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Infrastructure, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Cord Blood Banking Services: One-time collection and processing fee plus annual storage fees for long-term cryopreservation of cord blood stem cells. Parents pay for banking services with options to pay using Child Development Account (CDA).
- Cord Lining/Tissue Banking: Collection, processing and storage services for cord lining stem cells, provided on research/clinical trial basis
- Diagnostics Services: Non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening services
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Cord blood banking service with multiple coverage benefits |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Cordlife product offering
Product offeringCore offering
Cordlife provides private cord blood and cord lining/tissue stem cell banking services, collecting, processing, and cryogenically storing umbilical cord stem cells for potential future medical use. It also offers diagnostic services such as non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening for expectant families.
Product overview
Cordlife is a consumer healthcare company offering a comprehensive suite of stem cell banking and diagnostic services for mothers and children. The core product portfolio centers on cord blood and cord lining stem cell collection, processing, and cryogenic storage services. Beyond stem cell banking, the company provides diagnostic services including non-invasive prenatal testing (NIPT), paediatric vision screening, and newborn metabolic screening. The Cordlife Care 360° add-on package offers comprehensive protection including hospital bill coverage, global cord blood delivery, financial support for parental death/disability, viable match guarantees, and pregnancy complication coverage. The company operates through its subsidiaries including Cordlife Technologies Pte Ltd for cord lining/tissue banking services.
Differentiator
Problem solved
Functional benefit
Products and services
- Cord Blood Stem Cells Storage Collection, processing, and cryogenic storage of umbilical cord blood stem cells for potential future medical treatments. Cord blood can be used to treat over 80 diseases including blood cancers, immune disorders, and genetic disorders. For expectant parents choosing private/family banking.
- Cord Lining Stem Cells Storage Collection, processing and cryogenic storage of umbilical cord lining stem cells with potential applications in regenerative medicine, provided on a research/clinical trial basis with proprietary CellOptima assurances.
- Cordlife Care 360° Comprehensive protection package for banking clients offering hospital bill coverage (TransplantCare up to S$50,000), global cord blood delivery (Worldwide), financial support for parent death/disability (Protect), viable cord blood match guarantee (Pledge), pre-transplant testing coverage (Assure), professional indemnity insurance (Guard), and pregnancy complication coverage (Shield).
- Non-Invasive Prenatal Testing (NIPT) Prenatal diagnostic service offered as part of Cordlife's comprehensive suite of diagnostics services for expectant mothers.
- Paediatric Vision Screening Paediatric vision screening service for children offered as part of Cordlife's comprehensive suite of diagnostics services.
- Newborn Metabolic Screening Newborn metabolic screening service for early detection of metabolic conditions, offered as part of Cordlife's diagnostics suite.
- Cordlife Circle Loyalty program for existing Cordlife customers providing exclusive benefits and rewards.
Quantifiable outcome
- Over 600,000 parents in Asia trust Cordlife for cord blood banking
- +2 more outcomes
Companies that use Cordlife
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Cordlife technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cordlife partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Stemlife Berhad (Malaysia)coreMajority-owned subsidiary of Cordlife Group. Provides full stem cell banking services in Malaysia. Through this subsidiary, Cordlife has an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife.
- Thai Stemlife (Thailand)coreThailand's largest private cord blood bank. Cordlife has an indirect stake through its majority-owned subsidiary Stemlife Berhad in Malaysia.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Cordlife competitors and assessment
Company assessmentEmerging players
- Cells4Life: UK-based private cord blood and tissue bank offering comparable collection, processing, and cryogenic storage services with a multi-country footprint.
Direct peers
- Future Health Biobank: European-headquartered stem cell bank offering cord blood, cord tissue, and related banking services to families globally; closely comparable processing, storage, and consumer sales motion.
- Stemlife Berhad: Cordlife's own majority-owned Malaysian subsidiary offering cord blood banking in Malaysia and Thailand (via Thai Stemlife) — a directly comparable private banking network in adjacent ASEAN markets.
- StemCyte: US-based hybrid public-private cord blood bank providing both family banking and public registry services; comparable cryopreservation technology and clinical release track record.
- Cryoviva (Thailand): Pan-Asian private cord blood bank with presence in Thailand, Singapore, India and other Asian markets; competes head-to-head with Cordlife for the same expectant-parent segment.
Broad incumbents
- Cryo-Cell International: US-listed (NASDAQ: CCEL) cord blood and menstrual blood stem cell bank serving expectant parents; directly comparable business model of private/family cord blood banking with recurring storage revenue.
- ViaCord (Revvity/PerkinElmer): One of the largest US private cord blood banks operated by Revvity; comparable consumer healthcare service targeting expectant parents with one-time processing plus annual storage fees.
- Cord Blood Registry (CBR) by CooperCompanies: Long-established US private family cord blood bank under CooperSurgical (CooperCompanies); the clearest Western counterpart in scale, brand tenure, and stored-sample base.
Regional players
- Singapore Cord Blood Bank: Non-profit public cord blood bank in Singapore; competes in the same Singapore market with a public-registry rather than private-storage model.
- HealthBaby Hong Kong: Listed under Cordlife's Hong Kong navigation, HealthBaby is a major competing private cord blood bank in Hong Kong with overlapping expectant-parent customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Cordlife social profiles
Digital presenceCordlife financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cordlife leadership team
Management profileNumber of profiles
Profiles1 record
Cordlife subsidiaries and ownership
Company hierarchySubsidiaries3 records
Cordlife funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cordlife M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cordlife
What does Cordlife do?
Cordlife provides private cord blood and cord lining/tissue stem cell banking services, collecting, processing, and cryogenically storing umbilical cord stem cells for potential future medical use. It also offers diagnostic services such as non-invasive prenatal testing, paediatric vision screening, and newborn metabolic screening for expectant families.
Is Cordlife a public or private company?
Cordlife is a public company. It is classified as public and is currently operating.
When was Cordlife founded?
Cordlife was founded in 2001. It employs 51 to 100 people.
Where is Cordlife based?
Cordlife is headquartered in Singapore, Singapore, in the Asia region.
How does Cordlife make money?
Three revenue lines are on record. Cord Blood Banking Services are the primary driver. The others are cord Lining/Tissue Banking and diagnostics Services.
Who are Cordlife's main competitors?
Cells4Life is listed as an emerging player. Direct peers are Future Health Biobank, Stemlife Berhad, StemCyte and Cryoviva (Thailand). Broad incumbents are Cryo-Cell International, ViaCord (Revvity/PerkinElmer) and Cord Blood Registry (CBR) by CooperCompanies. Regional players are Singapore Cord Blood Bank and HealthBaby Hong Kong.
Does Cordlife have an API?
No public API is recorded for Cordlife.
What industry is Cordlife in?
Cordlife's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue). Its NAICS code is 621991.